Loading...
Searching Database & Compiling the results...
This process involves analyzing complex genetic data and may take a moment.
PDX model details
| PDX ID | 27.2A Cx |
|---|---|
| Host Strain(and Source) | NSG Source: Monash University |
| Host Strain Immune system Humanized | NO |
| Host Type | Castrate |
| Graft Site | Subcutaneous |
| Current Generation (* indicates number of generations grown in Castrate host) |
23 (4*) |
| Average PDX Generation Time (days +/- SEM) | 81 ± 9 |
| Tumour preparation | Tumor solid |
| Tumour Characterization Technology | Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin | Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed | Routine QA every 2-3 passages |
| Associated meta data | |
| PDX model availability | Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution | Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID | 34413304; 30049486 |
| Markers | 27.2A Cx |
|---|---|
| AR | Y |
| PSA | Y |
| PSMA | Y |
| NE | N |
| ERG | N |
This table displays curated CNVs
| PDX ID | Gene Symbol | CNV Log2 | CNV Copy | CNV Call | Experiments name | Platform | Reference genome |
|---|---|---|---|---|---|---|---|
| 27.2A Cx | MET | 0.853 | 3.614 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | BRAF | 0.759 | 3.385 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | EZH2 | 0.804 | 3.492 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | KMT2C | 0.804 | 3.492 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | CHD7 | 0.765 | 3.398 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | CHD7 | 0.648 | 3.133 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | SETDB1 | 0.586 | 3.003 | Gain | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | AR | -1.228 | 0.426 | GSR | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | CHD1 | -23.248 | 2.010e-07 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | RB1 | -26.409 | 2.240e-08 | Homdel | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | SPEN | -0.893 | 1.077 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | XPO1 | -0.756 | 1.184 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | PAX6 | -0.881 | 1.086 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | MSH2 | -0.943 | 1.040 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | MGA | -1.245 | 0.844 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | CDH1 | -1.400 | 0.758 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | ZFHX3 | -0.962 | 1.027 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | FANCA | -1.178 | 0.884 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | FANCA | -1.393 | 0.762 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | ZNRF3 | -0.880 | 1.087 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
| 27.2A Cx | SPEN | -1.163 | 0.893 | Loss | MURAL Prostate Cancer PDX collection | Targeted Twist Panel | hg19 |
Clinical Information
| Sample Number | 27.2A |
|---|---|
| Sample Site | Inguinal lymph node |
| Sample source | Autopsy |
| Pathology Tumour Diagnosis | Adenocarcinoma |
| Gleason Score | None |
| Primary Gleason Score | None |
| Secondary Gleason Score | None |
| Tertiary Gleason Score | None |
| ISUP Grade Group | |
| Tumour Grade | |
| D'Amico Risk Classification | |
| Tumour Volume (in cc) | 0.0 |
| Treatment Prior to Specimen Collection | ADT, docetaxel, abiraterone |
Patient Information
| Patient Number | 27 |
|---|---|
| Sex | Male |
| Diagnosis | Prostate Cancer |
| PSA at diagnosis (ng/mL) | 42 |
| Consent to share data | Yes, subject to ethical review |
| Patient Tumour Collection (Current Model) | |
|---|---|
| Tumour sample ID | 27.2A |
| Patient Age (binned in 5 year age groups) | 70-74 |
This table displays curated sequence variants
| PDX ID | Gene Symbol | Total Read Depth | Alternate Frequency | Consequence | Exon | GnomAD AF | CADD PHRED score | ClinVar significance | Platform | Experiments Name | Reference | Library Type | Instrument Type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 27.2A Cx | PCDH11X | 100 | 0.98 | Missense variant | '2/7 | . | 22.9 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.2A Cx | TH | 171 | 0.6 | Start lost | '1/14 | . | 21.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.2A Cx | TH | 171 | 0.6 | Start lost | '1/14 | . | 21.5 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.2A Cx | SON | 203 | 0.55 | Missense variant | '3/12 | . | 25.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.2A Cx | LHFPL3 | 271 | 0.54 | Missense variant | '1/5 | . | 26.7 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.2A Cx | CEP128 | 211 | 0.47 | Missense variant | '14/25 | . | 24.4 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.2A Cx | IGF2R | 266 | 0.42 | Missense variant | '16/48 | 3.28E-05 | 24 | - | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
| 27.2A Cx | AR | — | — | GSR | — | — | — | — | Targeted Twist Panel | MURAL Prostate Cancer PDX collection | hg19 | paired | NextSeq 500 |
No information in Drug dosing Table